F*CK CANCER
9 min readFrom Chapter 5 — Repurposed Medications of the book

Repurposed Drugs for Cancer: Metformin, Fenbendazole, Ivermectin

Why generic medications never designed for cancer are attracting serious research — the evidence, the mechanisms, and the caution. Chapter 5 of F*CK CANCER.

drug repurposingmetforminfenbendazoleivermectinoff-label cancer drugs

A new cancer drug takes well over a decade and billions of dollars to reach patients. But scattered through the existing pharmacy are generic medications with decades of safety data and — according to a growing body of research — unexpected anticancer activity. Chapter 5 of the book is devoted to these repurposed medicines, and it may be the most pragmatic chapter in the entire volume.

The logic of repurposing

A repurposed drug skips the most dangerous unknowns. Its safety profile is documented. Its interactions are mapped. It costs a fraction of a patented therapy. If laboratory evidence shows it also disrupts cancer biology, the path to clinical use is dramatically shorter than for a new molecule. The catch — and the book is direct about this — is that generic drugs attract almost no research funding, because no company can profit from them. That is exactly why independent research and informed patients matter so much here.

The compounds that lead the research

Metformin — the world's front-line diabetes drug — follows straight from the Warburg effect. If cancer depends on glucose, insulin, and mitochondrial dysfunction, a drug that lowers blood sugar, lowers insulin, and inhibits mitochondrial complex I pressures tumor metabolism from three directions at once. The epidemiological signal that launched the field was striking: diabetic patients taking metformin appeared to develop cancer less often than comparable patients on other treatments.

Fenbendazole — a veterinary antiparasitic — disrupts microtubules, the protein scaffolding cells must assemble to divide. That is the same principle behind established chemotherapy agents, and research groups have reported that it also interferes with cancer cells' glucose uptake. The honest status: compelling mechanism, preclinical evidence, and an urgent need for proper human trials.

Ivermectin — strip away the controversies that have nothing to do with oncology, and the cancer literature is surprisingly substantive: programmed cell death in cancer cell lines, inhibition of the WNT pathway that drives several tumor types, and reversal of a key chemotherapy-resistance mechanism in laboratory models.

The chapter profiles more: Dichloroacetate, which targets the metabolic switch directly; Low-Dose Naltrexone; Methylene Blue; and Artemisinin, the antimalarial with a documented taste for iron-hungry cancer cells.

The caution that has to come with the hope

Repurposed does not mean risk-free. These drugs interact with chemotherapy, with each other, and with the liver enzymes that process them. Doses in cancer research often differ from approved uses. This is a conversation for an oncology team willing to think integratively — armed with the structured questions in the book's encyclopedia entries — not a solo experiment.

The arsenal against cancer may already be larger than the pipeline suggests. Some of it has been sitting on pharmacy shelves all along.

Every repurposed medication in this chapter is mapped in the free Cure Finder with its evidence status, and Chapter 5 of the book gives each one a full profile — the research, the risks, and the questions to ask before you consider any of them.

Educational content, not medical advice. Never start or stop a medication without your medical team.

Frequently asked questions

Does metformin help fight cancer?

Metformin lowers insulin and activates AMPK, a pathway that restrains cell growth. People with diabetes taking it show lower rates of some cancers in observational studies, and trials are testing it as an add-on to standard treatment, though results so far are mixed.

What is the evidence for fenbendazole in cancer?

Fenbendazole, a veterinary dewormer, disrupts microtubules and glucose uptake in laboratory studies. Human evidence is limited to anecdotes like the Joe Tippens story — interesting but unproven, and not a substitute for treatment.

Why do researchers study repurposed drugs for cancer?

Existing drugs have known safety profiles and cost little, so they can move into trials fast. Because generics are unprofitable to develop, large trials are rare — which is exactly why independent research matters.